Table 6.
The effects of sulforaphane on cognitive impairment in Alzheimer’s disease (AD)-like animal models.
Model | Sulforaphane Dose | Findings | Ref. |
---|---|---|---|
5×FAD mice | every other day 10 mg/kg i.p. for 2 months | ameliorated cognitive deficits (Morris water maze tests and passive avoidance tests) | [31] |
3×Tg-AD mice | every other day 5 or 10 mg/kg i.p. for 2 months | ameliorated cognitive deficits (Morris water maze tests) | [31] |
daily 10 or 50 mg/kg p.o. 6 days/week for 2 months |
ameliorated memory deficit (novel object/location recognition tests and contextual fear conditioning tests) | [34] | |
APP/PS1 mice | daily 25 mg/kg p.o. for 5 months |
ameliorated cognitive dysfunction (open field and Morris water maze tests) | [35] |
PS1V97L mice | daily 5 mg/kg i.p. for 4 months | alleviated cognitive deficit (Morris water maze tests) | [32] |
AD-like mice induced by Aβ1–40 | daily 30 mg/kg i.p. for 6 days | ameliorated cognitive function (Y-maze and passive avoidance behavior tests) | [36] |
AD-like rat induced by Aβ42 | daily 5 mg/kg i.p. for 7 days | improved spatial learning | [37] |
i.p., intraperitoneally; p.o., per os (by mouth).